Mraz Amerine & Associates Inc. Has $243,000 Stake in Eli Lilly and Company $LLY

Mraz Amerine & Associates Inc. raised its stake in Eli Lilly and Company (NYSE:LLY) by 19.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 312 shares of the company’s stock after buying an additional 50 shares during the quarter. Mraz Amerine & Associates Inc.’s holdings in Eli Lilly and Company were worth $243,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in LLY. WestEnd Advisors LLC raised its position in shares of Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after purchasing an additional 21 shares during the period. Wealth Preservation Advisors LLC acquired a new stake in shares of Eli Lilly and Company during the first quarter worth about $27,000. Citizens National Bank Trust Department raised its position in shares of Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after purchasing an additional 27 shares during the period. Financial Gravity Asset Management Inc. acquired a new stake in shares of Eli Lilly and Company during the first quarter worth about $40,000. Finally, TD Capital Management LLC raised its position in shares of Eli Lilly and Company by 129.2% during the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after purchasing an additional 31 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Transactions at Eli Lilly and Company

In related news, Director J Erik Fyrwald purchased 1,565 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was purchased at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the purchase, the director directly owned 74,578 shares in the company, valued at $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Daniel Skovronsky purchased 1,000 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was bought at an average price of $634.40 per share, with a total value of $634,400.00. Following the completion of the purchase, the executive vice president owned 137,660 shares of the company’s stock, valued at approximately $87,331,504. This represents a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 4,514 shares of company stock valued at $2,894,841. 0.14% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on LLY shares. Wall Street Zen lowered Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 20th. Guggenheim dropped their price target on Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating on the stock in a research report on Wednesday, August 13th. HSBC increased their price objective on Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. JPMorgan Chase & Co. decreased their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating for the company in a report on Tuesday, September 16th. Finally, Leerink Partners reiterated a “market perform” rating and set a $715.00 price objective on shares of Eli Lilly and Company in a report on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $938.94.

Eli Lilly and Company Stock Down 0.1%

LLY stock opened at $844.30 on Wednesday. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The business has a 50 day moving average price of $736.97 and a two-hundred day moving average price of $766.03. The company has a market cap of $799.09 billion, a price-to-earnings ratio of 55.18, a P/E/G ratio of 1.18 and a beta of 0.47. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $937.00.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. The firm had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business’s revenue was up 37.6% compared to the same quarter last year. During the same period last year, the company earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.